Catalyst, Rumor, Ideas
In Play: ImClone Systems Inc.
By
Jan 24, 2006, 16:47

ImClone Systems Incorporated (NASDAQ:IMCL) announced today that the Board of Directors has engaged Lazard to conduct, in conjunction with management, a full review of the Company's strategic alternatives to maximize shareholder value. These alternatives could include a merger, sale or strategic alliance. The Company is proceeding in consultation with its existing partners as the process moves forward.

INFO SOURCES

ImClone Systems Incorporated (Nasdaq: IMCL)

FIRMS

ImClone Systems Incorporated is committed to advancing oncology care by developing and commercializing a portfolio of targeted biologic treatments designed to address the medical needs of patients with a variety of cancers. The Company's research and development programs include growth factor blockers and angiogenesis inhibitors. ImClone Systems' strategy is to become a fully integrated biopharmaceutical company, taking its development programs from the research stage to the market. ImClone Systems' headquarters and research operations are located in New York City, with additional administration and manufacturing facilities in Branchburg, New Jersey.